<?xml version='1.0' encoding='UTF-8'?>
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Nat Sci Sleep</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nat Sci Sleep</journal-id>
      <journal-id journal-id-type="publisher-id">NSS</journal-id>
      <journal-id journal-id-type="pmc">nss</journal-id>
      <journal-title-group>
        <journal-title>Nature and Science of Sleep</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1179-1608</issn>
      <publisher>
        <publisher-name>Dove</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32158294</article-id>
      <article-id pub-id-type="pmc">6986247</article-id>
      <article-id pub-id-type="publisher-id">238255</article-id>
      <article-id pub-id-type="doi">10.2147/NSS.S238255</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Obstructive Sleep Apnea Screening with a 4-Item Instrument, Named GOAL Questionnaire: Development, Validation and Comparative Study with No-Apnea, STOP-Bang, and NoSAS</article-title>
        <alt-title alt-title-type="running-authors">Duarte et al</alt-title>
        <alt-title alt-title-type="running-title">Duarte et al</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2611-4001</contrib-id>
          <name>
            <surname>Duarte</surname>
            <given-names>Ricardo LM</given-names>
          </name>
          <xref ref-type="aff" rid="AFF0001">1</xref>
          <xref ref-type="aff" rid="AFF0002">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Magalhães-da-Silveira</surname>
            <given-names>Flavio J</given-names>
          </name>
          <xref ref-type="aff" rid="AFF0001">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3539-8392</contrib-id>
          <name>
            <surname>Oliveira-e-Sá</surname>
            <given-names>Tiago S</given-names>
          </name>
          <xref ref-type="aff" rid="AFF0003">3</xref>
          <xref ref-type="aff" rid="AFF0004">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Silva</surname>
            <given-names>Joana A</given-names>
          </name>
          <xref ref-type="aff" rid="AFF0005">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3250-6738</contrib-id>
          <name>
            <surname>Mello</surname>
            <given-names>Fernanda CQ</given-names>
          </name>
          <xref ref-type="aff" rid="AFF0002">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8195-6036</contrib-id>
          <name>
            <surname>Gozal</surname>
            <given-names>David</given-names>
          </name>
          <xref ref-type="corresp" rid="AN0001"/>
          <xref ref-type="aff" rid="AFF0006">6</xref>
        </contrib>
        <aff id="AFF0001"><label>1</label><institution>Sleep - Laboratório de Estudo dos Distúrbios do Sono, Centro Médico BarraShopping</institution>, <addr-line>Rio de Janeiro</addr-line>, <country>Brazil</country></aff>
        <aff id="AFF0002"><label>2</label><institution>Instituto de Doenças do Tórax, Universidade Federal do Rio de Janeiro</institution>, <addr-line>Rio de Janeiro</addr-line>, <country>Brazil</country></aff>
        <aff id="AFF0003"><label>3</label><institution>Hospital de Santa Marta, Centro Hospitalar Lisboa Central</institution>, <addr-line>Lisbon</addr-line>, <country>Portugal</country></aff>
        <aff id="AFF0004"><label>4</label><institution>NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa</institution>, <addr-line>Lisbon</addr-line>, <country>Portugal</country></aff>
        <aff id="AFF0005"><label>5</label><institution>Clínica São Vicente, Rede D’Or</institution>, <addr-line>Rio de Janeiro</addr-line>, <country>Brazil</country></aff>
        <aff id="AFF0006"><label>6</label><institution>Department of Child Health, University of Missouri School of Medicine</institution>, <addr-line>Columbia</addr-line>, <addr-line>MO</addr-line>, <country>USA</country></aff>
      </contrib-group>
      <author-notes>
        <corresp id="AN0001">Correspondence: David Gozal <institution>Department of Child Health, University of Missouri School of Medicine</institution>, <addr-line>Columbia</addr-line>, <addr-line>MO</addr-line>, <country>USA</country> Email drdavidgozal@gmail.com</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>23</day>
        <month>1</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2020</year>
      </pub-date>
      <volume>12</volume>
      <fpage>57</fpage>
      <lpage>67</lpage>
      <history>
        <date date-type="received">
          <day>12</day>
          <month>11</month>
          <year>2019</year>
        </date>
        <date date-type="accepted">
          <day>14</day>
          <month>1</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2020 Duarte et al.</copyright-statement>
        <copyright-year>2020</copyright-year>
        <copyright-holder>Duarte et al.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <sec id="S2001">
          <title>Background</title>
          <p><citation_analysis attribute="neither">Obstructive sleep apnea (OSA) is a very prevalent disorder. Here, we aimed to develop and validate a practical questionnaire with yes-or-no answers, and to compare its performance with other well-validated instruments: No-Apnea, STOP-Bang, and NoSAS.</citation_analysis></p>
        </sec>
        <sec id="S2002">
          <title>Methods</title>
          <p><citation_analysis attribute="positive">A cross-sectional study containing consecutively selected sleep-lab subjects underwent full polysomnography. A 4-item model, named GOAL questionnaire (gender, obesity, age, and loud snoring), was developed and subsequently validated, with item-scoring of 0–4 points (≥2 points indicating high risk for OSA). Discrimination was assessed by area under the curve (AUC), while predictive parameters were calculated using contingency tables. OSA severity was classified based on conventionally accepted apnea/hypopnea index thresholds: ≥5.0/h (OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥5</sub></citation_analysis><citation_analysis attribute="neither">), ≥15.0/h (OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥15</sub></citation_analysis><citation_analysis attribute="neither">), and ≥30.0/h (OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥30</sub></citation_analysis><citation_analysis attribute="neither">).</citation_analysis></p>
        </sec>
        <sec id="S2003">
          <title>Results</title>
          <p><citation_analysis attribute="neither">Overall, 7377 adults were grouped into two large and independent cohorts: derivation (n = 3771) and validation (n = 3606). In the derivation cohort, screening of OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥5</sub></citation_analysis><citation_analysis attribute="neither">, OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥15</sub></citation_analysis><citation_analysis attribute="neither">, and OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥30</sub></citation_analysis><citation_analysis attribute="neither"> revealed that GOAL questionnaire achieved sensitivity ranging from 83.3% to 94.0% and specificity ranging from 62.4% to 38.5%. In the validation cohort, screening of OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥5</sub></citation_analysis><citation_analysis attribute="neither">, OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥15</sub></citation_analysis><citation_analysis attribute="neither">, and OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥30</sub></citation_analysis><citation_analysis attribute="neither">, corroborated validation steps with sensitivity ranging from 83.7% to 94.2% and specificity from 63.4% to 37.7%. In both cohorts, discriminatory ability of GOAL questionnaire for screening of OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥5</sub></citation_analysis><citation_analysis attribute="neither">, OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥15</sub></citation_analysis><citation_analysis attribute="neither">, and OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥30</sub></citation_analysis><citation_analysis attribute="neither"> was similar to No-Apnea, STOP-Bang or NoSAS.</citation_analysis></p>
        </sec>
        <sec id="S2004">
          <title>Conclusion</title>
          <p><citation_analysis attribute="neither">All four instruments had similar performance, leading to a possible greater practical implementation of the GOAL questionnaire, a simple instrument with only four parameters easily obtained during clinical evaluation.</citation_analysis></p>
        </sec>
      </abstract>
      <kwd-group kwd-group-type="author">
        <title>Keywords</title>
        <kwd>obstructive sleep apnea</kwd>
        <kwd>polysomnography</kwd>
        <kwd>screening</kwd>
        <kwd>questionnaire</kwd>
        <kwd>diagnosis</kwd>
      </kwd-group>
      <counts>
        <fig-count count="5"/>
        <table-count count="5"/>
        <ref-count count="38"/>
        <page-count count="11"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="S0001">
      <title>Introduction</title>
      <p><citation_analysis attribute="neither">Obstructive sleep apnea (OSA) is characterized by frequent partial or complete upper airway collapse during sleep, resulting in intermittent hypoxemia and sleep fragmentation.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="positive"> There is growing evidence that OSA plays a key role in the pathogenesis of cardiovascular and metabolic diseases, as well as a clear association with increased overall mortality and medical costs.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0002" ref-type="bibr">2</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0003" ref-type="bibr">3</xref></citation_analysis><citation_analysis attribute="neither"> OSA is very prevalent disease,</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0004" ref-type="bibr">4</xref></citation_analysis><citation_analysis attribute="neither">–</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0006" ref-type="bibr">6</xref></citation_analysis><citation_analysis attribute="positive"> being that most recent estimates have suggested that nearly a billion of people may be affected, with about 425 million individuals, aged 30 to 69, suffering from moderate to severe OSA, worldwide.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0007" ref-type="bibr">7</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">The gold standard for the diagnosis of OSA is an attended in-lab overnight polysomnography (PSG) test.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="neither"> However, this costly method is not readily available to a large number of patients with suspected OSA, especially in regions with limited economic resources.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0008" ref-type="bibr">8</xref></citation_analysis><citation_analysis attribute="positive"> Due to the high frequency of OSA, there is a significant cost in evaluating all subjects with suspected OSA, leading to long waiting times for testing.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0009" ref-type="bibr">9</xref></citation_analysis><citation_analysis attribute="positive"> In this context, portable diagnostic methods have been extensively implemented as an alternative for the diagnosis of OSA in those adults exhibiting a high pretest probability and absence of significant comorbidity.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0001" ref-type="bibr">1</xref></citation_analysis></p>
      <p><citation_analysis attribute="negative">The various screening instruments that have merged over the years have been generally predicated on the clinical, demographic and anthropometric parameters that constitute the major risk factors for OSA.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0008" ref-type="bibr">8</xref></citation_analysis><citation_analysis attribute="neither"> The STOP-Bang questionnaire is an 8-item acronym that can be easily completed.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0010" ref-type="bibr">10</xref></citation_analysis><citation_analysis attribute="positive"> It was developed and later validated in surgical subjects having a high prevalence of OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥5</sub></citation_analysis><citation_analysis attribute="neither">: 73% (derivation cohort) and 69% (validation cohort).</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0010" ref-type="bibr">10</xref></citation_analysis><citation_analysis attribute="positive"> Subsequently, it was widely validated in several different settings: sleep clinic patients, surgical patients, and general population.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0011" ref-type="bibr">11</xref></citation_analysis><citation_analysis attribute="neither">–</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0016" ref-type="bibr">16</xref></citation_analysis><citation_analysis attribute="positive"> Conversely, NoSAS score was derived and validated in population-based cohorts (HypnoLaus and EPISONO, respectively).</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0017" ref-type="bibr">17</xref></citation_analysis><citation_analysis attribute="positive"> Afterwards, this score was also validated in different settings, reporting adequate performance as screening model for OSA: in a multiethnic Asian cohort, in a hospital-based sample, in depressive subjects, and in a sleep clinic.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0018" ref-type="bibr">18</xref></citation_analysis><citation_analysis attribute="neither">–</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0022" ref-type="bibr">22</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">The No-Apnea</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0023" ref-type="bibr">23</xref></citation_analysis><citation_analysis attribute="positive"> tool is a newly developed and validated screening instrument that includes only two objective parameters: neck circumference (NC) and age, with a total score ranging from 0 to 9 (cutoff point ≥3 classifies patients at high risk for OSA). In derivation and validation cohorts, No-Apnea showed adequate performance in OSA screening, with a discriminatory ability that was similar and indistinguishable from the performance of either STOP-Bang or NoSAS.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0023" ref-type="bibr">23</xref></citation_analysis><citation_analysis attribute="positive"> Although No-Apnea has been subsequently validated in selected clinical populations,</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0024" ref-type="bibr">24</xref></citation_analysis><citation_analysis attribute="neither">–</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0026" ref-type="bibr">26</xref></citation_analysis><citation_analysis attribute="positive"> and displayed adequate predictive performance, some points deserve to be highlighted: i) absence of subjective variables may result in more difficult applicability, especially in regions with a lower prevalence of OSA, such as in primary care; ii) presence of age ≥55 years, already sufficient to classify individuals at high risk for the diagnosis of OSA, possibly limits its use in older populations; and iii) because it contains different scores for each parameter, it may be difficult to adopt and implement, particularly in general clinical practice settings.</citation_analysis></p>
      <p><citation_analysis attribute="positive">Based on such concerns, we aimed to develop a practical and concise questionnaire that would include both objective and subjective variables, with yes-or-no dichotomous answers. To this effect, we designed the present study into two parts: i) derivation and validation of a proposed tool for screening OSA in adults, and ii) comparison with three other widely validated OSA screening instruments: No-Apnea score, STOP-Bang questionnaire, and NoSAS score.</citation_analysis></p>
    </sec>
    <sec id="S0002">
      <title>Methods</title>
      <sec id="S0002-S2001">
        <title>Study Design and Patient Selection</title>
        <p><citation_analysis attribute="neither">This was a cross-sectional study, comprising the period from January 2017 to June 2019, including adults which were consecutively referred for PSG evaluation due to suspected sleep disordered breathing by their attending physicians. Then, all subjects were grouped into two separate cohorts: derivation (from January 2017 to February 2018) and validation (from May 2018 to June 2019). Inclusion criteria consisted of individuals of both genders, aged ≥18 years and with suspected of OSA, while exclusion criteria were: previously diagnosed OSA, use of home sleep study for diagnosis, incomplete clinical data and technically inadequate PSG. In case the same individual underwent more than one PSG, only the test with the longest total sleep time was included. All sleep tests were conducted in a Brazilian single-center located in the city of Rio de Janeiro: SLEEP – Laboratório de Estudo dos Distúrbios do Sono.</citation_analysis></p>
        <p><citation_analysis attribute="neither">On the evening of PSG, clinical, demographic and anthropometric data were systematically obtained from all participants by trained sleep laboratory technicians: gender, age, body mass index (BMI), NC, self-reported comorbidities (hypertension and diabetes mellitus), OSA-related symptoms (snoring, observed apnea, gasping/choking, and tiredness), and Epworth Sleepiness Scale (ESS).</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0027" ref-type="bibr">27</xref></citation_analysis><citation_analysis attribute="negative"> The ESS is an 8-item questionnaire (each item is scored from 0 to 3 points, with a final score from 0 to 24 points), which subjectively measures excessive daytime sleepiness by a score ≥11 points.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0027" ref-type="bibr">27</xref></citation_analysis><citation_analysis attribute="neither"> BMI was calculated dividing the weight in kilograms by the square of the height in meters (kg/m</citation_analysis><citation_analysis attribute="positive"><sup>2</sup></citation_analysis><citation_analysis attribute="positive">), while NC (cm) was measured using a tape measure, with its upper edge placed below the laryngeal prominence and applied perpendicularly along the neck axis.</citation_analysis></p>
      </sec>
      <sec id="S0002-S2002">
        <title>Ethical Considerations</title>
        <p><citation_analysis attribute="neither">The study protocol (No. 1.764.165) was approved by the Research Ethics Committee of the Federal University of Rio de Janeiro (UFRJ) and adhered to standard previously set by the Declaration of Helsinki. All participants provided written informed consent, being that anonymity of all recruited individuals was guaranteed throughout the study process.</citation_analysis></p>
      </sec>
      <sec id="S0002-S2003">
        <title>Screening Instruments</title>
        <p><citation_analysis attribute="positive">The No-Apnea (final score from 0 to 9, high risk with 3 or more points) contains two objective parameters: NC is scored in three values: 1 (37.0–39.9 cm), 3 (40.0–42.9 cm), and 6 (≥43.0 cm), while age is scored as follows: 1 (35–44 years), 2 (45–54 years), and 3 (≥55 years).</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0023" ref-type="bibr">23</xref></citation_analysis><citation_analysis attribute="negative"> The STOP-Bang (final score from 0 to 8, high risk with 3 or more points) consists of 8 yes-or-no questions (1 point for each affirmative answer): loud snoring, tiredness, observed apnea, hypertension, BMI &gt; 35 kg/m</citation_analysis><citation_analysis attribute="positive"><sup>2</sup></citation_analysis><citation_analysis attribute="neither">, age &gt;50 years, NC &gt; 40 cm, and male gender.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0010" ref-type="bibr">10</xref></citation_analysis><citation_analysis attribute="neither"> The NoSAS allocates 4 points for having a NC &gt;40 cm, 3 points for having a BMI of 25–29 kg/m</citation_analysis><citation_analysis attribute="positive"><sup>2</sup></citation_analysis><citation_analysis attribute="neither"> or 5 points for having a BMI ≥ 30 kg/m</citation_analysis><citation_analysis attribute="positive"><sup>2</sup></citation_analysis><citation_analysis attribute="positive">, 2 points for habitual snoring, 4 points for age &gt;55 years, and 2 points for men; this instrument is considered positive with a score ≥8 points (from 0 to 17 points).</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0017" ref-type="bibr">17</xref></citation_analysis></p>
      </sec>
      <sec id="S0002-S2004">
        <title>Sleep Studies</title>
        <p><citation_analysis attribute="neither">All subjects underwent an attended, in-lab PSG (EMBLA</citation_analysis><citation_analysis attribute="positive"><sup>®</sup></citation_analysis><citation_analysis attribute="neither"> S7000, Embla Systems, Inc., Broomfield, Colorado, United States) consisting of continuous monitoring of electroencephalogram, electrooculogram, electromyogram (chin and legs), electrocardiogram, airflow, thoracic and abdominal impedance belts, oxygen saturation, snoring microphone and sensors for body position. Polysomnographic records were manually interpreted by two board-certified sleep physicians, according to a guideline previously published in 2012 by the American Academy of Sleep Medicine (AASM),</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0028" ref-type="bibr">28</xref></citation_analysis><citation_analysis attribute="neither"> which were blinded to the values of all screening instruments collected prior to PSG. Apneas were classified from a drop ≥90% of baseline airflow lasting at least 10 s, while hypopneas were classified from a ≥30% pre-event drop over ≥10 s associated with desaturation of oxygen ≥3% or an arousal.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0028" ref-type="bibr">28</xref></citation_analysis><citation_analysis attribute="neither"> The AHI was calculated as the number of apnea plus hypopnea/total sleep time (in hours). Polysomnographic diagnosis of OSA was based on apnea/hypopnea index (AHI) ≥5.0/h and its severity was classified as follows: ≥5.0/h as any OSA (OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥5</sub></citation_analysis><citation_analysis attribute="neither">), ≥15.0/h as moderate/severe OSA (OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥15</sub></citation_analysis><citation_analysis attribute="neither">), and ≥30.0/h as severe OSA (OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥30</sub></citation_analysis><citation_analysis attribute="neither">).</citation_analysis></p>
      </sec>
      <sec id="S0002-S2005">
        <title>Statistical Analysis</title>
        <p><citation_analysis attribute="positive">Data analysis was carried out using SPSS for Windows (version 21.0; SPSS; Chicago, IL, United States). Results are presented as mean ± standard deviation for continuous variables and as frequency (n) with percentage (%) for categorical variables. The groups were compared using the chi-square test for categorical variables, while Student’s </citation_analysis><citation_analysis attribute="positive"><italic>t</italic></citation_analysis><citation_analysis attribute="neither">-test and univariate analysis of variance (ANOVA) were used for numerical variables. The modeling of the proposed instrument was initially based on 10 variables often associated with OSA diagnosis: male gender, age ≥50 years, NC ≥40 cm, BMI ≥30 kg/m</citation_analysis><citation_analysis attribute="positive"><sup>2</sup></citation_analysis><citation_analysis attribute="neither">, loud snoring, observed apnea, hypertension, diabetes mellitus, tiredness, and gasping/choking. The chosen cutoff points for age and BMI were based on the highest odds ratio (OR) obtained for OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥15</sub></citation_analysis><citation_analysis attribute="neither"> diagnosis: age ≥50 years (OR: 1.911; 95% confidence interval [CI]: 1.668–2.189) versus age ≥55 years (OR: 1.817; 95% CI: 1.566–2.108) and BMI ≥ 30 kg/m</citation_analysis><citation_analysis attribute="positive"><sup>2</sup></citation_analysis><citation_analysis attribute="neither"> (OR: 2.563; 95% CI: 2.243–2.928) versus BMI ≥ 35 kg/m</citation_analysis><citation_analysis attribute="positive"><sup>2</sup></citation_analysis><citation_analysis attribute="neither"> (OR: 2.088; 95% CI: 1.826–2.388). Similarly, we used loud snoring and not the presence of snoring by obtaining a higher OR for OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥15</sub></citation_analysis><citation_analysis attribute="neither"> diagnosis: OR: 5.454 (95% CI: 3.972–7.490) versus 3.801 (95% CI: 3.300–4.377). The NC ≥ 40 cm has been chosen as this is the threshold used in the STOP-Bang and NoSAS instruments.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0010" ref-type="bibr">10</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0017" ref-type="bibr">17</xref></citation_analysis><citation_analysis attribute="positive"> Firstly, these 10 chosen variables were evaluated by univariate analyses, where the outcome was an AHI ≥ 15.0/h, a conventionally accepted cutoff point for classifying clinically relevant OSA. Sequentially, clinically relevant variables (p &lt; 0.10 in the univariate analysis) were included in a multivariate logistic regression model with AHI ≥ 15.0/h being the dependent variable. Performance of the newly developed instrument was calculated as follows: i) discrimination by the Receiver Operating Characteristic (ROC) curves and area under the curve (AUC); ii) calibration assessed by the Hosmer–Lemeshow test (p &lt; 0.05 was considered as poor calibration); iii) 2x2 contingency tables (sensitivity, specificity, positive predictive value [PPV], and negative predictive value [NPV]); and iv) correlation through the Spearman coefficient (r</citation_analysis><citation_analysis attribute="positive"><sub>s</sub></citation_analysis><citation_analysis attribute="positive">). As Hosmer–Lemeshow test is very sensitive to sample size, we chose a smaller subset of randomly selected patients (n = 1000) to evaluate calibration. An AUC &gt; 0.7 was considered as clinically significant, being that AUCs were compared using a previously described algorithm.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0029" ref-type="bibr">29</xref></citation_analysis><citation_analysis attribute="positive"> All predictive parameters were calculated at three AHI thresholds (5.0/h, 15.0/h, and 30.0/h) and reported with their respective 95% CIs. A two-tailed p-value &lt;0.05 was considered as statistically significant.</citation_analysis></p>
      </sec>
    </sec>
    <sec id="S0003">
      <title>Results</title>
      <p><citation_analysis attribute="neither">The flowchart of the study is showed in </citation_analysis><citation_analysis attribute="positive"><xref rid="F0001" ref-type="fig">Figure 1</xref></citation_analysis><citation_analysis attribute="neither">, being that 7377 subjects were consecutively allocated into two independent cohorts: one for derivation (n = 3771) and one for validation (n = 3606). According to </citation_analysis><citation_analysis attribute="positive"><xref rid="T0001" ref-type="table">Table 1</xref></citation_analysis><citation_analysis attribute="positive">, no clinical or polysomnographic parameter showed a statistically significant difference between derivation and validation cohorts, except for total sleep time (p = 0.047) and arousal index (p = 0.031). Prevalence of OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥5</sub></citation_analysis><citation_analysis attribute="neither">, OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥15</sub></citation_analysis><citation_analysis attribute="neither">, and OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥30</sub></citation_analysis><citation_analysis attribute="positive"> showed no statistically significant differences between derivation and validation cohorts: 79.1% versus 78.8% (p = 0.753), 57.7% versus 57.0% (p = 0.604), and 37.8% versus 35.7% (p = 0.070); respectively.</citation_analysis><citation_analysis attribute="positive"><table-wrap id="T0001" orientation="portrait" position="float"><label>Table 1</label><caption><p><citation_analysis attribute="neither">Patient Characteristics</citation_analysis></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Parameters</th><th rowspan="1" colspan="1">Derivation Cohort (n = 3771)</th><th rowspan="1" colspan="1">Validation Cohort (n = 3606)</th><th rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><bold>Clinical data</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> Male gender (%)</td><td rowspan="1" colspan="1">1983 (52.6)</td><td rowspan="1" colspan="1">1961 (54.4)</td><td rowspan="1" colspan="1">0.123</td></tr><tr><td rowspan="1" colspan="1"> Age (years)</td><td rowspan="1" colspan="1">45.9 ± 14.6</td><td rowspan="1" colspan="1">45.7 ± 14.6</td><td rowspan="1" colspan="1">0.593</td></tr><tr><td rowspan="1" colspan="1"> BMI (kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1">33.1 ± 7.9</td><td rowspan="1" colspan="1">32.9 ± 7.7</td><td rowspan="1" colspan="1">0.437</td></tr><tr><td rowspan="1" colspan="1"> NC (cm)</td><td rowspan="1" colspan="1">40.5 ± 5.0</td><td rowspan="1" colspan="1">40.5 ± 4.8</td><td rowspan="1" colspan="1">0.998</td></tr><tr><td rowspan="1" colspan="1"> ESS (points)</td><td rowspan="1" colspan="1">9.8 ± 5.0</td><td rowspan="1" colspan="1">9.8 ± 5.1</td><td rowspan="1" colspan="1">0.766</td></tr><tr><td rowspan="1" colspan="1"> Hypertension (%)</td><td rowspan="1" colspan="1">1531 (40.6)</td><td rowspan="1" colspan="1">1404 (38.9)</td><td rowspan="1" colspan="1">0.147</td></tr><tr><td rowspan="1" colspan="1"> Diabetes mellitus (%)</td><td rowspan="1" colspan="1">470 (12.5)</td><td rowspan="1" colspan="1">436 (12.1)</td><td rowspan="1" colspan="1">0.645</td></tr><tr><td rowspan="1" colspan="1"> Loud snoring (%)</td><td rowspan="1" colspan="1">2465 (65.4)</td><td rowspan="1" colspan="1">2291 (63.5)</td><td rowspan="1" colspan="1">0.103</td></tr><tr><td rowspan="1" colspan="1"> Observed apnea (%)</td><td rowspan="1" colspan="1">1893 (50.2)</td><td rowspan="1" colspan="1">1847 (51.2)</td><td rowspan="1" colspan="1">0.389</td></tr><tr><td rowspan="1" colspan="1"> Gasping/choking (%)</td><td rowspan="1" colspan="1">1503 (39.9)</td><td rowspan="1" colspan="1">1488 (41.3)</td><td rowspan="1" colspan="1">0.226</td></tr><tr><td rowspan="1" colspan="1"> Tiredness (%)</td><td rowspan="1" colspan="1">2711 (71.9)</td><td rowspan="1" colspan="1">2607 (72.3)</td><td rowspan="1" colspan="1">0.716</td></tr><tr><td rowspan="1" colspan="1"><bold>Polysomnographic data</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> Total sleep time (min)</td><td rowspan="1" colspan="1">338.5 ± 71.7</td><td rowspan="1" colspan="1">342.1 ± 68.2</td><td rowspan="1" colspan="1">0.047</td></tr><tr><td rowspan="1" colspan="1"> NREM sleep stage (%)</td><td rowspan="1" colspan="1">83.6 ± 7.8</td><td rowspan="1" colspan="1">83.4 ± 7.8</td><td rowspan="1" colspan="1">0.296</td></tr><tr><td rowspan="1" colspan="1"> REM sleep stage (%)</td><td rowspan="1" colspan="1">15.9 ± 7.8</td><td rowspan="1" colspan="1">16.2 ± 7.9</td><td rowspan="1" colspan="1">0.179</td></tr><tr><td rowspan="1" colspan="1"> Arousal index (n/h)</td><td rowspan="1" colspan="1">31.1 ± 26.0</td><td rowspan="1" colspan="1">29.8 ± 24.8</td><td rowspan="1" colspan="1">0.031</td></tr><tr><td rowspan="1" colspan="1"> AHI (n/h)</td><td rowspan="1" colspan="1">28.9 ± 28.1</td><td rowspan="1" colspan="1">27.7 ± 26.9</td><td rowspan="1" colspan="1">0.058</td></tr><tr><td rowspan="1" colspan="1"> Mean SpO<sub>2</sub> (%)</td><td rowspan="1" colspan="1">93.5 ± 3.2</td><td rowspan="1" colspan="1">93.4 ± 3.5</td><td rowspan="1" colspan="1">0.528</td></tr><tr><td rowspan="1" colspan="1"> Nadir SpO<sub>2</sub> (%)</td><td rowspan="1" colspan="1">81.8 ± 9.3</td><td rowspan="1" colspan="1">81.9 ± 9.4</td><td rowspan="1" colspan="1">0.680</td></tr><tr><td rowspan="1" colspan="1"><bold>AHI (n/h)</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> ≥5.0/h (%)</td><td rowspan="1" colspan="1">2984 (79.1)</td><td rowspan="1" colspan="1">2842 (78.8)</td><td rowspan="1" colspan="1">0.753</td></tr><tr><td rowspan="1" colspan="1"> ≥15.0/h (%)</td><td rowspan="1" colspan="1">2174 (57.7)</td><td rowspan="1" colspan="1">2057 (57.0)</td><td rowspan="1" colspan="1">0.604</td></tr><tr><td rowspan="1" colspan="1"> ≥30.0/h (%)</td><td rowspan="1" colspan="1">1424 (37.8)</td><td rowspan="1" colspan="1">1288 (35.7)</td><td rowspan="1" colspan="1">0.070</td></tr></tbody></table><table-wrap-foot><fn><p><citation_analysis attribute="positive"><bold>Note:</bold></citation_analysis><citation_analysis attribute="positive"> Numeric and categorical variables were reported as mean ± SD and n (%), respectively.</citation_analysis></p></fn><fn><p><citation_analysis attribute="positive"><bold>Abbreviations:</bold></citation_analysis><citation_analysis attribute="neither"> BMI, body mass index; NC, neck circumference; ESS, Epworth Sleepiness Scale; NREM, non-rapid eye movement; REM, rapid eye movement; AHI, apnea/hypopnea index; SpO</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="neither">, oxygen saturation.</citation_analysis></p></fn></table-wrap-foot></table-wrap></citation_analysis><citation_analysis attribute="positive">
</citation_analysis><citation_analysis attribute="positive"><fig id="F0001" fig-type="figure" orientation="portrait" position="float"><label>Figure 1</label><caption><p><citation_analysis attribute="neither">The flowchart of the patients.</citation_analysis></p><p><citation_analysis attribute="positive"><bold>Abbreviations:</bold></citation_analysis><citation_analysis attribute="neither"> OSA, obstructive sleep apnea; PSG, polysomnography.</citation_analysis></p></caption><graphic content-type="print-only" xlink:href="NSS-12-57-g0001"/></fig></citation_analysis></p>
      <sec id="S0003-S2001">
        <title>Modeling</title>
        <p><citation_analysis attribute="positive"><xref rid="T0002" ref-type="table">Table 2</xref></citation_analysis><citation_analysis attribute="neither"> shows the seven independent predictive parameters for screening for OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥15</sub></citation_analysis><citation_analysis attribute="neither">. Diabetes mellitus and gasping/choking, although initially tested as possible OSA predictors, were subsequently excluded because they are not independent variables for OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥15</sub></citation_analysis><citation_analysis attribute="neither"> diagnosis. As can be seen in </citation_analysis><citation_analysis attribute="positive"><xref rid="T0002" ref-type="table">Table 2</xref></citation_analysis><citation_analysis attribute="positive">, these seven parameters were ranked according to adjusted OR: the main parameter was male gender, followed by age ≥50 years, loud snoring, BMI ≥ 30 kg/m</citation_analysis><citation_analysis attribute="positive"><sup>2</sup></citation_analysis><citation_analysis attribute="neither">, NC ≥ 40 cm, observed apnea, and hypertension.</citation_analysis><citation_analysis attribute="positive"><table-wrap id="T0002" orientation="portrait" position="float"><label>Table 2</label><caption><p><citation_analysis attribute="neither">Univariate and Multivariate Analyses of Clinical Parameters According to AHI ≥ 15.0/h (Derivation Cohort; n = 3771)</citation_analysis></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Parameters</th><th colspan="2" rowspan="1">Univariate Analysis</th><th colspan="2" rowspan="1">Multivariate Analysis</th></tr><tr><th rowspan="1" colspan="1">Unadjusted OR (95% CI)</th><th rowspan="1" colspan="1">p</th><th rowspan="1" colspan="1">Adjusted OR (95% CI)</th><th rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Male gender</td><td rowspan="1" colspan="1">3.394 (2.964–3.885)</td><td rowspan="1" colspan="1">&lt; 0.001</td><td rowspan="1" colspan="1">2.831 (2.356–3.402)</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Age ≥ 50 years</td><td rowspan="1" colspan="1">1.911 (1.668–2.189)</td><td rowspan="1" colspan="1">&lt; 0.001</td><td rowspan="1" colspan="1">2.572 (2.159–3.064)</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Loud snoring</td><td rowspan="1" colspan="1">5.454 (3.972–7.490)</td><td rowspan="1" colspan="1">&lt; 0.001</td><td rowspan="1" colspan="1">2.402 (2.037–2.832)</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">BMI ≥ 30 kg/m<sup>2</sup></td><td rowspan="1" colspan="1">2.563 (2.243–2.928)</td><td rowspan="1" colspan="1">&lt; 0.001</td><td rowspan="1" colspan="1">2.315 (1.932–2.774)</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">NC ≥ 40 cm</td><td rowspan="1" colspan="1">4.323 (3.759–4.972)</td><td rowspan="1" colspan="1">&lt; 0.001</td><td rowspan="1" colspan="1">1.937 (1.602–2.343)</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Observed apnea</td><td rowspan="1" colspan="1">2.894 (2.531–3.309)</td><td rowspan="1" colspan="1">&lt; 0.001</td><td rowspan="1" colspan="1">1.670 (1.412–1.975)</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Hypertension</td><td rowspan="1" colspan="1">2.147 (1.874–2.459)</td><td rowspan="1" colspan="1">&lt; 0.001</td><td rowspan="1" colspan="1">1.254 (1.060–1.484)</td><td rowspan="1" colspan="1">0.008</td></tr><tr><td rowspan="1" colspan="1">Diabetes mellitus</td><td rowspan="1" colspan="1">1.841 (1.494–2.269)</td><td rowspan="1" colspan="1">&lt; 0.001</td><td rowspan="1" colspan="1">1.140 (0.892–1.457)</td><td rowspan="1" colspan="1">0.295</td></tr><tr><td rowspan="1" colspan="1">Gasping/choking</td><td rowspan="1" colspan="1">1.342 (1.175–1.533)</td><td rowspan="1" colspan="1">&lt; 0.001</td><td rowspan="1" colspan="1">1.022 (0.867–1.204)</td><td rowspan="1" colspan="1">0.799</td></tr><tr><td rowspan="1" colspan="1">Tiredness</td><td rowspan="1" colspan="1">0.913 (0.790–1.054)</td><td rowspan="1" colspan="1">0.226</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">–</td></tr></tbody></table><table-wrap-foot><fn><p><citation_analysis attribute="positive"><bold>Abbreviations:</bold></citation_analysis><citation_analysis attribute="neither"> AHI, apnea/hypopnea index; BMI, body mass index; NC, neck circumference; OR, odds ratio; CI, confidence interval.</citation_analysis></p></fn></table-wrap-foot></table-wrap></citation_analysis><citation_analysis attribute="positive">
</citation_analysis></p>
        <p><citation_analysis attribute="positive">From these data, several possible models were tested using the main clinical parameters previously found. </citation_analysis><citation_analysis attribute="positive"><xref rid="F0002" ref-type="fig">Figure 2</xref></citation_analysis><citation_analysis attribute="neither"> summarizes the discrimination of possible models containing from 3 to 7 parameters, which exemplifies why a 4-item model was ultimately chosen, since discriminatory power did not significantly increase with the addition of a 5th (NC ≥ 40 cm), 6th (observed apnea) or 7th variable (hypertension). This 4-item instrument, because it contains only yes-or-no dichotomous answers, reaches a final score of 0–4 points (</citation_analysis><citation_analysis attribute="positive"><xref rid="T0003" ref-type="table">Table 3</xref></citation_analysis><citation_analysis attribute="neither">), being later named by the acronym GOAL (gender, obesity, age, and loud snoring) questionnaire.</citation_analysis><citation_analysis attribute="positive"><table-wrap id="T0003" orientation="portrait" position="float"><label>Table 3</label><caption><p><citation_analysis attribute="neither">The GOAL Questionnaire</citation_analysis></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Parameters</th><th rowspan="1" colspan="1">Points</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">G - Male gender</td><td rowspan="1" colspan="1">No = 0 Yes = 1</td></tr><tr><td rowspan="1" colspan="1">O - Obesity: body mass index ≥ 30 kg/m<sup>2</sup></td><td rowspan="1" colspan="1">No = 0 Yes = 1</td></tr><tr><td rowspan="1" colspan="1">A - Age ≥ 50 years</td><td rowspan="1" colspan="1">No = 0 Yes = 1</td></tr><tr><td rowspan="1" colspan="1">L - Loud snoring</td><td rowspan="1" colspan="1">No = 0 Yes = 1</td></tr></tbody></table><table-wrap-foot><fn><p><citation_analysis attribute="positive"><bold>Note:</bold></citation_analysis><citation_analysis attribute="neither"> The points for each variable are added, totaling a final score of 0–4 points.</citation_analysis></p></fn></table-wrap-foot></table-wrap></citation_analysis><citation_analysis attribute="positive">
</citation_analysis><citation_analysis attribute="positive"><fig id="F0002" fig-type="figure" orientation="portrait" position="float"><label>Figure 2</label><caption><p><citation_analysis attribute="neither">Graphical representation of several models sequentially constructed with the main independent variables for screening of moderate/severe obstructive sleep apnea (OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥15</sub></citation_analysis><citation_analysis attribute="neither">). 3-item model: male gender, age ≥50 years, and loud snoring; 4-item model: 3-item model plus body mass index ≥30 kg/m</citation_analysis><citation_analysis attribute="positive"><sup>2</sup></citation_analysis><citation_analysis attribute="positive">, 5-item model: 4-item model plus neck circumference ≥40 cm, 6-item model: 5-item model plus observed apnea, and 7-item model: 6-item model plus hypertension. The 3-item model reported discrimination statistically lower than that obtained by 4-item model (p &lt; 0.001). The 4-item model had a similar discrimination when compared to the 5-item, 6-item or 7-item models (p-values: 0.184, 0.070, and 0.086; respectively). Estimates reported as area under the curve (95% confidence interval).</citation_analysis></p></caption><graphic content-type="print-only" xlink:href="NSS-12-57-g0002"/></fig></citation_analysis></p>
      </sec>
      <sec id="S0003-S2002">
        <title>Predictive Parameters</title>
        <p><citation_analysis attribute="neither">Mean AHI values increased linearly in parallel with increasing GOAL questionnaire scores (from 0 to 4 points): i) derivation cohort: from 3.6 ± 5.7/h to 53.3 ± 26.1/h (p-value for trend &lt;0.001) and ii) validation cohort: from 3.6 ± 5.8/h to 50.8 ± 27.1/h (p-value for trend &lt;0.001); </citation_analysis><citation_analysis attribute="positive"><xref rid="F0003" ref-type="fig">Figure 3</xref></citation_analysis><citation_analysis attribute="neither">. In both datasets, GOAL was positively correlated with AHI: </citation_analysis><citation_analysis attribute="positive"><italic>r<sub>s</sub></italic></citation_analysis><citation_analysis attribute="neither"> = 0.559 with p &lt; 0.001 (derivation cohort) and </citation_analysis><citation_analysis attribute="positive"><italic>r<sub>s</sub></italic></citation_analysis><citation_analysis attribute="neither"> = 0.554 with p &lt; 0.001 (validation cohort). In the derivation cohort, GOAL questionnaire showed adequate calibration for screening of OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥5</sub></citation_analysis><citation_analysis attribute="neither">, OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥15</sub></citation_analysis><citation_analysis attribute="neither">, and OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥30</sub></citation_analysis><citation_analysis attribute="positive"> assessed by Hosmer–Lemeshow test: 11.563 (p = 0.172), 5.135 (p = 0.743), and 5.355 (p = 0.719); respectively. Similarly, in the validation cohort, GOAL displayed adequate calibration for screening of OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥5</sub></citation_analysis><citation_analysis attribute="neither">, OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥15</sub></citation_analysis><citation_analysis attribute="neither">, and OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥30</sub></citation_analysis><citation_analysis attribute="positive"> assessed by Hosmer–Lemeshow test: 9.855 (p = 0.197), 3.921 (p = 0.864), and 5.799 (p = 0.670); respectively.</citation_analysis><citation_analysis attribute="positive"><fig id="F0003" fig-type="figure" orientation="portrait" position="float"><label>Figure 3</label><caption><p><citation_analysis attribute="neither">Mean apnea/hypopnea index (AHI) values obtained by polysomnography according to GOAL questionnaire scores (from 0 to 4 points).</citation_analysis></p></caption><graphic content-type="print-only" xlink:href="NSS-12-57-g0003"/></fig></citation_analysis></p>
        <p><citation_analysis attribute="positive">Predictive performance of the GOAL questionnaire is shown in </citation_analysis><citation_analysis attribute="positive"><xref rid="T0004" ref-type="table">Table 4</xref></citation_analysis><citation_analysis attribute="positive"> (derivation cohort). We used a cutoff point ≥2 to classify patients at high risk for OSA. This strategy focused on privileging sensitivity over specificity, aiming at reducing the false-negative rate. The frequency of subjects classified as high risk for OSA through the four screening instruments is shown in </citation_analysis><citation_analysis attribute="positive"><xref rid="F0004" ref-type="fig">Figure 4</xref></citation_analysis><citation_analysis attribute="neither">.</citation_analysis><citation_analysis attribute="positive"><table-wrap id="T0004" orientation="portrait" position="float"><label>Table 4</label><caption><p><citation_analysis attribute="neither">Predictive Parameters of the GOAL Questionnaire (Derivation Cohort; n = 3771)</citation_analysis></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th colspan="4" rowspan="1">GOAL Questionnaire Scores</th></tr><tr><th rowspan="1" colspan="1">≥ 1 versus &lt; 1</th><th rowspan="1" colspan="1">≥ 2 versus &lt; 2</th><th rowspan="1" colspan="1">≥ 3 versus &lt; 3</th><th rowspan="1" colspan="1">4 versus &lt; 4</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><bold>AHI ≥ 5.0/h</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> Sensitivity</td><td rowspan="1" colspan="1">98.4 (98.0–98.8)</td><td rowspan="1" colspan="1">83.3 (82.6–84.1)</td><td rowspan="1" colspan="1">48.0 (47.4–48.5)</td><td rowspan="1" colspan="1">8.20 (8.00–8.30)</td></tr><tr><td rowspan="1" colspan="1"> Specificity</td><td rowspan="1" colspan="1">20.5 (18.8–21.8)</td><td rowspan="1" colspan="1">62.4 (59.5–65.2)</td><td rowspan="1" colspan="1">88.9 (86.6–90.9)</td><td rowspan="1" colspan="1">99.5 (98.6–99.8)</td></tr><tr><td rowspan="1" colspan="1"> PPV</td><td rowspan="1" colspan="1">82.4 (82.1–82.7)</td><td rowspan="1" colspan="1">89.4 (88.5–90.2)</td><td rowspan="1" colspan="1">94.3 (93.1–95.3)</td><td rowspan="1" colspan="1">98.4 (95.7–99.5)</td></tr><tr><td rowspan="1" colspan="1"> NPV</td><td rowspan="1" colspan="1">77.4 (71.2–82.6)</td><td rowspan="1" colspan="1">49.7 (47.4–52.0)</td><td rowspan="1" colspan="1">31.1 (30.3–31.8)</td><td rowspan="1" colspan="1">22.2 (22.0–22.3)</td></tr><tr><td rowspan="1" colspan="1"><bold>AHI ≥ 15.0/h</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> Sensitivity</td><td rowspan="1" colspan="1">99.6 (99.2–99.8)</td><td rowspan="1" colspan="1">89.8 (88.7–90.8)</td><td rowspan="1" colspan="1">56.5 (55.3–57.7)</td><td rowspan="1" colspan="1">10.5 (10.0–10.8)</td></tr><tr><td rowspan="1" colspan="1"> Specificity</td><td rowspan="1" colspan="1">12.5 (11.9–12.7)</td><td rowspan="1" colspan="1">48.0 (46.5–49.4)</td><td rowspan="1" colspan="1">81.8 (80.1–83.3)</td><td rowspan="1" colspan="1">98.6 (97.9–99.1)</td></tr><tr><td rowspan="1" colspan="1"> PPV</td><td rowspan="1" colspan="1">60.8 (60.5–60.9)</td><td rowspan="1" colspan="1">70.1 (69.3–70.9)</td><td rowspan="1" colspan="1">80.9 (79.1–82.5)</td><td rowspan="1" colspan="1">91.2 (86.9–94.3)</td></tr><tr><td rowspan="1" colspan="1"> NPV</td><td rowspan="1" colspan="1">95.7 (91.7–97.9)</td><td rowspan="1" colspan="1">77.5 (75.1–79.8)</td><td rowspan="1" colspan="1">58.0 (56.9–59.1)</td><td rowspan="1" colspan="1">44.7 (44.4–44.9)</td></tr><tr><td rowspan="1" colspan="1"><bold>AHI ≥ 30.0/h</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> Sensitivity</td><td rowspan="1" colspan="1">99.9 (99.4–100.0)</td><td rowspan="1" colspan="1">94.0 (92.8–95.1)</td><td rowspan="1" colspan="1">65.8 (63.9–67.7)</td><td rowspan="1" colspan="1">13.6 (12.6–14.5)</td></tr><tr><td rowspan="1" colspan="1"> Specificity</td><td rowspan="1" colspan="1">8.80 (8.50–8.89)</td><td rowspan="1" colspan="1">38.5 (37.7–39.1)</td><td rowspan="1" colspan="1">75.2 (74.0–76.3)</td><td rowspan="1" colspan="1">97.6 (97.0–98.1)</td></tr><tr><td rowspan="1" colspan="1"> PPV</td><td rowspan="1" colspan="1">39.9 (39.7–40.0)</td><td rowspan="1" colspan="1">48.1 (47.5–48.7)</td><td rowspan="1" colspan="1">61.6 (59.8–63.4)</td><td rowspan="1" colspan="1">77.6 (72.0–82.4)</td></tr><tr><td rowspan="1" colspan="1"> NPV</td><td rowspan="1" colspan="1">99.0 (96.2–99.8)</td><td rowspan="1" colspan="1">91.4 (89.6–93.0)</td><td rowspan="1" colspan="1">78.4 (77.1–79.6)</td><td rowspan="1" colspan="1">65.1 (64.7–65.4)</td></tr></tbody></table><table-wrap-foot><fn><p><citation_analysis attribute="positive"><bold>Note:</bold></citation_analysis><citation_analysis attribute="neither"> Data are presented as estimates (95% confidence intervals).</citation_analysis></p></fn><fn><p><citation_analysis attribute="positive"><bold>Abbreviations:</bold></citation_analysis><citation_analysis attribute="positive"> AHI, apnea/hypopnea index; PPV, positive predictive value; NPV, negative predictive value.</citation_analysis></p></fn></table-wrap-foot></table-wrap></citation_analysis><citation_analysis attribute="positive">
</citation_analysis><citation_analysis attribute="positive"><fig id="F0004" fig-type="figure" orientation="portrait" position="float"><label>Figure 4</label><caption><p><citation_analysis attribute="positive">Percentage of individuals assessed as high risk for diagnosis of obstructive sleep apnea by four screening instruments: GOAL questionnaire, No-Apnea score, STOP-Bang questionnaire, and NoSAS score.</citation_analysis></p></caption><graphic content-type="print-only" xlink:href="NSS-12-57-g0004"/></fig></citation_analysis></p>
        <p><citation_analysis attribute="positive"><xref rid="T0005" ref-type="table">Table 5</xref></citation_analysis><citation_analysis attribute="positive"> compares GOAL questionnaire with three other previously validated tools: No-Apnea, STOP-Bang, and NoSAS. In the derivation cohort, for screening of OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥5</sub></citation_analysis><citation_analysis attribute="neither">, OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥15</sub></citation_analysis><citation_analysis attribute="neither">, and OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥30</sub></citation_analysis><citation_analysis attribute="neither">, GOAL questionnaire presented sensitivities ranging from 83.3% to 94.0% and specificities ranging from 62.4% to 38.5%. In the validation cohort, for screening of OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥5</sub></citation_analysis><citation_analysis attribute="neither">, OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥15</sub></citation_analysis><citation_analysis attribute="neither">, and OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥30</sub></citation_analysis><citation_analysis attribute="neither">, GOAL questionnaire showed sensitivity values ranging from 83.7% to 94.2% and specificity values ranging from 63.4% to 37.7%. In both cohorts, for diagnosis of OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥5</sub></citation_analysis><citation_analysis attribute="neither">, OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥15</sub></citation_analysis><citation_analysis attribute="neither">, and OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥30</sub></citation_analysis><citation_analysis attribute="neither">, STOP-Bang always presented the highest sensitivity, while NoSAS always presented the highest specificity. In both datasets and at all OSA severity levels, GOAL questionnaire showed high sensitivity. As expected, for all four instruments, as AHI thresholds increased, a corresponding increase in sensitivity and a reduction in specificity occurred.</citation_analysis><citation_analysis attribute="positive"><table-wrap id="T0005" orientation="portrait" position="float"><label>Table 5</label><caption><p><citation_analysis attribute="neither">Predictive Parameters of the OSA Screening Models</citation_analysis></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th colspan="4" rowspan="1">Screening Instruments</th></tr><tr><th rowspan="1" colspan="1">GOAL</th><th rowspan="1" colspan="1">No-Apnea</th><th rowspan="1" colspan="1">STOP-Bang</th><th rowspan="1" colspan="1">NoSAS</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><bold>Derivation cohort</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><bold>AHI ≥ 5.0/h</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> Sensitivity</td><td rowspan="1" colspan="1">83.3 (82.6–84.1)</td><td rowspan="1" colspan="1">84.3 (83.5–85.0)</td><td rowspan="1" colspan="1">87.2 (86.5–88.0)</td><td rowspan="1" colspan="1">71.5 (70.7–72.3)</td></tr><tr><td rowspan="1" colspan="1"> Specificity</td><td rowspan="1" colspan="1">62.4 (59.5–65.2)</td><td rowspan="1" colspan="1">56.3 (53.4–59.2)</td><td rowspan="1" colspan="1">50.6 (47.7–53.4)</td><td rowspan="1" colspan="1">71.0 (68.1–73.8)</td></tr><tr><td rowspan="1" colspan="1"> PPV</td><td rowspan="1" colspan="1">89.4 (88.5–90.2)</td><td rowspan="1" colspan="1">88.0 (87.2–88.8)</td><td rowspan="1" colspan="1">87.0 (86.2–87.7)</td><td rowspan="1" colspan="1">90.3 (89.4–91.3)</td></tr><tr><td rowspan="1" colspan="1"> NPV</td><td rowspan="1" colspan="1">49.7 (47.4–52.0)</td><td rowspan="1" colspan="1">48.6 (46.0–51.0)</td><td rowspan="1" colspan="1">51.1 (48.2–53.9)</td><td rowspan="1" colspan="1">39.7 (38.0–41.2)</td></tr><tr><td rowspan="1" colspan="1"><bold>AHI ≥ 15.0/h</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> Sensitivity</td><td rowspan="1" colspan="1">89.8 (88.7–90.8)</td><td rowspan="1" colspan="1">89.8 (88.7–90.9)</td><td rowspan="1" colspan="1">91.7 (90.7–92.6)</td><td rowspan="1" colspan="1">79.0 (77.7–80.2)</td></tr><tr><td rowspan="1" colspan="1"> Specificity</td><td rowspan="1" colspan="1">48.0 (46.5–49.4)</td><td rowspan="1" colspan="1">43.3 (41.8–44.7)</td><td rowspan="1" colspan="1">37.4 (36.1–38.7)</td><td rowspan="1" colspan="1">59.6 (57.9–61.3)</td></tr><tr><td rowspan="1" colspan="1"> PPV</td><td rowspan="1" colspan="1">70.1 (69.3–70.9)</td><td rowspan="1" colspan="1">68.3 (67.5–69.1)</td><td rowspan="1" colspan="1">66.6 (65.9–67.3)</td><td rowspan="1" colspan="1">72.7 (71.5–73.8)</td></tr><tr><td rowspan="1" colspan="1"> NPV</td><td rowspan="1" colspan="1">77.5 (75.1–79.8)</td><td rowspan="1" colspan="1">75.8 (73.2–78.2)</td><td rowspan="1" colspan="1">76.8 (73.9–79.4)</td><td rowspan="1" colspan="1">67.6 (65.6–69.5)</td></tr><tr><td rowspan="1" colspan="1"><bold>AHI ≥ 30.0/h</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> Sensitivity</td><td rowspan="1" colspan="1">94.0 (92.8–95.1)</td><td rowspan="1" colspan="1">93.2 (91.9–94.3)</td><td rowspan="1" colspan="1">95.6 (94.4–96.5)</td><td rowspan="1" colspan="1">85.3 (83.6–86.8)</td></tr><tr><td rowspan="1" colspan="1"> Specificity</td><td rowspan="1" colspan="1">38.5 (37.7–39.1)</td><td rowspan="1" colspan="1">34.7 (33.9–35.4)</td><td rowspan="1" colspan="1">30.5 (29.8–31.1)</td><td rowspan="1" colspan="1">51.1 (50.1–52.1)</td></tr><tr><td rowspan="1" colspan="1"> PPV</td><td rowspan="1" colspan="1">48.1 (47.5–48.7)</td><td rowspan="1" colspan="1">46.4 (45.8–47.0)</td><td rowspan="1" colspan="1">45.5 (44.9–45.9)</td><td rowspan="1" colspan="1">51.4 (50.4–52.4)</td></tr><tr><td rowspan="1" colspan="1"> NPV</td><td rowspan="1" colspan="1">91.4 (89.6–93.0)</td><td rowspan="1" colspan="1">89.4 (87.3–91.2)</td><td rowspan="1" colspan="1">91.9 (89.8–93.6)</td><td rowspan="1" colspan="1">85.1 (83.4–86.7)</td></tr><tr><td rowspan="1" colspan="1"><bold>Validation cohort</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><bold>AHI ≥ 5.0/h</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> Sensitivity</td><td rowspan="1" colspan="1">83.7 (82.9–84.4)</td><td rowspan="1" colspan="1">85.2 (84.4–86.0)</td><td rowspan="1" colspan="1">88.0 (87.2–88.8)</td><td rowspan="1" colspan="1">71.8 (71.0–72.6)</td></tr><tr><td rowspan="1" colspan="1"> Specificity</td><td rowspan="1" colspan="1">63.4 (60.4–66.2)</td><td rowspan="1" colspan="1">56.8 (53.9–59.7)</td><td rowspan="1" colspan="1">52.1 (49.2–54.9)</td><td rowspan="1" colspan="1">70.2 (67.2–73.0)</td></tr><tr><td rowspan="1" colspan="1"> PPV</td><td rowspan="1" colspan="1">89.5 (88.6–90.3)</td><td rowspan="1" colspan="1">88.0 (87.2–88.8)</td><td rowspan="1" colspan="1">87.2 (86.5–88.0)</td><td rowspan="1" colspan="1">89.9 (88.9–90.9)</td></tr><tr><td rowspan="1" colspan="1"> NPV</td><td rowspan="1" colspan="1">51.1 (48.7–53.3)</td><td rowspan="1" colspan="1">50.8 (48.1–53.3)</td><td rowspan="1" colspan="1">53.9 (50.9–56.7)</td><td rowspan="1" colspan="1">40.1 (38.3–41.7)</td></tr><tr><td rowspan="1" colspan="1"><bold>AHI ≥ 15.0/h</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> Sensitivity</td><td rowspan="1" colspan="1">89.2 (88.0–90.2)</td><td rowspan="1" colspan="1">90.4 (89.3–91.5)</td><td rowspan="1" colspan="1">92.5 (91.5–93.5)</td><td rowspan="1" colspan="1">79.0 (77.7–80.3)</td></tr><tr><td rowspan="1" colspan="1"> Specificity</td><td rowspan="1" colspan="1">46.8 (45.3–48.2)</td><td rowspan="1" colspan="1">42.5 (41.0–43.9)</td><td rowspan="1" colspan="1">37.8 (36.4–39.0)</td><td rowspan="1" colspan="1">58.5 (56.7–60.2)</td></tr><tr><td rowspan="1" colspan="1"> PPV</td><td rowspan="1" colspan="1">69.0 (68.1–69.8)</td><td rowspan="1" colspan="1">67.6 (66.8–68.4)</td><td rowspan="1" colspan="1">66.4 (65.6–67.1)</td><td rowspan="1" colspan="1">71.6 (70.5–72.8)</td></tr><tr><td rowspan="1" colspan="1"> NPV</td><td rowspan="1" colspan="1">76.5 (74.0–78.8)</td><td rowspan="1" colspan="1">77.0 (74.3–79.5)</td><td rowspan="1" colspan="1">79.2 (76.3–81.8)</td><td rowspan="1" colspan="1">67.7 (65.7–69.7)</td></tr><tr><td rowspan="1" colspan="1"><bold>AHI ≥ 30.0/h</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> Sensitivity</td><td rowspan="1" colspan="1">94.2 (92.8–95.3)</td><td rowspan="1" colspan="1">93.8 (92.4–95.0)</td><td rowspan="1" colspan="1">96.6 (95.5–97.5)</td><td rowspan="1" colspan="1">85.7 (83.9–87.4)</td></tr><tr><td rowspan="1" colspan="1"> Specificity</td><td rowspan="1" colspan="1">37.7 (36.9–38.3)</td><td rowspan="1" colspan="1">33.4 (32.7–34.1)</td><td rowspan="1" colspan="1">30.0 (29.4–30.5)</td><td rowspan="1" colspan="1">49.8 (48.8–50.7)</td></tr><tr><td rowspan="1" colspan="1"> PPV</td><td rowspan="1" colspan="1">45.6 (45.0–46.2)</td><td rowspan="1" colspan="1">43.9 (43.3–44.5)</td><td rowspan="1" colspan="1">43.4 (42.9–43.8)</td><td rowspan="1" colspan="1">48.7 (47.7–49.6)</td></tr><tr><td rowspan="1" colspan="1"> NPV</td><td rowspan="1" colspan="1">92.1 (90.3–93.6)</td><td rowspan="1" colspan="1">90.6 (88.6–92.4)</td><td rowspan="1" colspan="1">94.0 (92.1–95.6)</td><td rowspan="1" colspan="1">86.2 (84.5–87.9)</td></tr></tbody></table><table-wrap-foot><fn><p><citation_analysis attribute="positive"><bold>Note:</bold></citation_analysis><citation_analysis attribute="neither"> Data are presented as estimates (95% confidence intervals).</citation_analysis></p></fn><fn><p><citation_analysis attribute="positive"><bold>Abbreviations:</bold></citation_analysis><citation_analysis attribute="positive"> AHI, apnea/hypopnea index; PPV, positive predictive value; NPV, negative predictive value.</citation_analysis></p></fn></table-wrap-foot></table-wrap></citation_analysis><citation_analysis attribute="positive">
</citation_analysis></p>
      </sec>
      <sec id="S0003-S2003">
        <title>Comparing Discriminatory Ability</title>
        <p><citation_analysis attribute="positive"><xref rid="F0005" ref-type="fig">Figure 5</xref></citation_analysis><citation_analysis attribute="positive"> shows the discrimination obtained by the four screening instruments: in both cohorts and at all OSA severity levels, there were no statistically significant differences in the discriminatory ability of the GOAL questionnaire when compared to No-Apnea, STOP-Bang or NoSAS in screening of OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥5</sub></citation_analysis><citation_analysis attribute="neither">, OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥15</sub></citation_analysis><citation_analysis attribute="neither">, and OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥30</sub></citation_analysis><citation_analysis attribute="neither">.</citation_analysis><citation_analysis attribute="positive"><fig id="F0005" fig-type="figure" orientation="portrait" position="float"><label>Figure 5</label><caption><p><citation_analysis attribute="positive">Discriminatory ability, reported as area under the curve (95% confidence interval), of GOAL questionnaire, No-Apnea score, STOP-Bang questionnaire, and NoSAS score for screening of obstructive sleep apnea (OSA) assessed by an apnea/hypopnea index (AHI) ≥5.0/h (OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥5</sub></citation_analysis><citation_analysis attribute="neither">), ≥15.0/h (OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥15</sub></citation_analysis><citation_analysis attribute="neither">), and ≥30.0/h (OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥30</sub></citation_analysis><citation_analysis attribute="neither">). In the derivation cohort, GOAL questionnaire had similar discrimination to No-Apnea, STOP-Bang, and NoSAS for predicting OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥5</sub></citation_analysis><citation_analysis attribute="neither"> (p-values: 0.476, 0.928, and 0.532; respectively), OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥15</sub></citation_analysis><citation_analysis attribute="neither"> (p-values: 0.404, 0.778, and 0.354; respectively), and OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥30</sub></citation_analysis><citation_analysis attribute="neither"> (p-values: 0.557, 0.123, and 0.674; respectively). In the validation cohort, GOAL questionnaire showed equivalent discrimination to No-Apnea, STOP-Bang, and NoSAS for predicting OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥5</sub></citation_analysis><citation_analysis attribute="neither"> (p-values: 0.593, 0.786, and 0.115; respectively); OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥15</sub></citation_analysis><citation_analysis attribute="neither"> (p-values: 0.927, 0.465, and 0.651; respectively), and OSA</citation_analysis><citation_analysis attribute="positive"><sub>≥30</sub></citation_analysis><citation_analysis attribute="neither"> (p-values: 0.936, 0.293, and 0.749; respectively).</citation_analysis></p></caption><graphic content-type="print-only" xlink:href="NSS-12-57-g0005"/></fig></citation_analysis></p>
      </sec>
    </sec>
    <sec id="S0004">
      <title>Discussion</title>
      <p><citation_analysis attribute="positive">Current findings show that in a sleep-lab setting, a simple and practical 4-item model, which we have denominated GOAL questionnaire (male gender, obesity with BMI ≥30 kg/m</citation_analysis><citation_analysis attribute="positive"><sup>2,</sup></citation_analysis><citation_analysis attribute="positive"> age ≥50 years, and loud snoring), achieves adequate and reproducible predictive performance for OSA screening at all severity levels. Furthermore, its discriminatory ability was similar from that of three previously validated and widely used screening instruments for OSA: No-Apnea score, STOP-Bang questionnaire, and NoSAS score. Moreover, obtaining score ≥2 versus &lt;2 points to rank, respectively, at high or low risk allowed an increase in specificity values compared to No-Apnea, while concurrently preserving a relatively high sensitivity, especially at most severe levels.</citation_analysis></p>
      <p><citation_analysis attribute="neither">Sensitivity and specificity of a screening model are usually inversely related and high sensitivity often comes at the expense of specificity.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0008" ref-type="bibr">8</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="positive"> In the context of OSA, which is a very prevalent disease and often associated with significant morbidity, it may be more important that the screening method has high sensitivity, with consequent reduction in the false-negative rate.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0008" ref-type="bibr">8</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="positive"> As expected, all four screening instruments (GOAL, No-Apnea, STOP-Bang, and NoSAS) showed increased sensitivity in parallel with increasing AHI thresholds (from 5.0/h to 30.0/h). On the other hand, specificity decreased in the most severe forms of OSA, which can result in a considerable number of false positives.</citation_analysis></p>
      <p><citation_analysis attribute="neither">Although our newly developed questionnaire contains twice as many parameters as No-Apnea, it may be easier to respond, score and interpret, since its construct is predicated on yes-or-no answers leading to easy calculation of the cumulative score and simple attribution of risk. In contrast, No-Apnea contains several sub-items being scored from 0 to 9 points. Another noteworthy fact is that No-Apnea derivation and validation study</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0023" ref-type="bibr">23</xref></citation_analysis><citation_analysis attribute="neither"> was designed with retrospectively recruited subjects, while the present study was conducted with two independent cohorts of prospectively enrolled subjects. In addition, logistic regression employed for No-Apnea model development</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0023" ref-type="bibr">23</xref></citation_analysis><citation_analysis attribute="positive"> was performed with binary outcome (AHI ≥ 5.0/h), while in the development of the GOAL questionnaire we employed AHI ≥ 15.0/h, a threshold often implicated as a clinically relevant demarcation for OSA. Our recently proposed instrument contains only one subjective variable (loud snoring), similar to NoSAS (presence of snoring), but well below the STOP-Bang which has four subjective variables (loud snoring, observed apnea, tiredness, and hypertension). Using a limited number of subjective parameters possibly could result in greater applicability of the instrument and less possibility of bias.</citation_analysis></p>
      <p><citation_analysis attribute="negative">Another feature of the current instrument is that by increasing its scores (from 0 to 4 points) there was a linear increase in AHI obtained by PSG. This property may further translate into a valuable tool for health professionals in defining the level of risk and relative certainty when attempting to identify those patients with a higher or lower probability of having a diagnosis of OSA. The risk escalation characteristic has also been previously described with the STOP-Bang questionnaire, whereby increasing values obtained from STOP-Bang (from 0 to 8 points) were associated with an increased likelihood of having OSA.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0031" ref-type="bibr">31</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">The four clinical parameters (gender, BMI, age, snoring) employed for the elaboration of our screening instrument are well-established predictive factors for OSA. Regarding clinical symptomatology, men with OSA usually have typical symptoms such as snoring and observed apnea, while women with OSA often report symptoms that are considered atypical, such as insomnia, morning headache, and fatigue.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0032" ref-type="bibr">32</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0033" ref-type="bibr">33</xref></citation_analysis><citation_analysis attribute="neither"> Based on polysomnographic findings, women have a lower prevalence of OSA than men, but with a clear increase in frequency after menopause.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0032" ref-type="bibr">32</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0033" ref-type="bibr">33</xref></citation_analysis><citation_analysis attribute="neither"> Unlike No-Apnea,</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0023" ref-type="bibr">23</xref></citation_analysis><citation_analysis attribute="neither"> the chosen measure of obesity was BMI over NC: this finding may translate into a better balance of its components between genders, since NC is a variable that is arguably higher in men than in women.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0032" ref-type="bibr">32</xref></citation_analysis><citation_analysis attribute="neither">–</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0034" ref-type="bibr">34</xref></citation_analysis><citation_analysis attribute="neither"> OSA prevalence increases with age, with some studies reporting a high prevalence of OSA in the elderly.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0035" ref-type="bibr">35</xref></citation_analysis><citation_analysis attribute="negative"> The only subjective variable that was chosen in our model was loud snoring, since snoring intensity increases as OSA becomes more severe.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0036" ref-type="bibr">36</xref></citation_analysis><citation_analysis attribute="neither"> In addition, this question from the STOP-Bang questionnaire “Do you snore loudly?” has already undergone cross-cultural adaptation to the Portuguese language spoken in Brazil.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0037" ref-type="bibr">37</xref></citation_analysis></p>
      <sec id="S0004-S2001">
        <title>Limitations and Strengths</title>
        <p><citation_analysis attribute="negative">Our study has some limitations that should be highlighted: the study population was based on sleep-lab referral patients (subjects with a high pretest probability), and therefore the possibility of selection bias is plausible. As the predictive values of a screening model are affected by disease prevalence,</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0038" ref-type="bibr">38</xref></citation_analysis><citation_analysis attribute="positive"> future studies should be conducted to assess the performance of the GOAL questionnaire in other population groups. In addition, it was conducted in a single-center and did not preferably include individuals belonging to populations with their own distinct anthropometric characteristics (eg, Asian or African populations), thus requiring future additional external validation. Conversely, we should also point out several features of the present study that should strengthen the ability to implement the proposed instrument: it was developed and validated from two very large and representative cohorts, with prospectively recruited participants undergoing the same diagnostic test for OSA (overnight full PSG) and with the same diagnostic criteria recommended by AASM.</citation_analysis><citation_analysis attribute="positive"><xref rid="CIT0028" ref-type="bibr">28</xref></citation_analysis></p>
      </sec>
    </sec>
    <sec id="S0005">
      <title>Conclusions</title>
      <p><citation_analysis attribute="neither">All instruments (GOAL questionnaire, No-Apnea score, STOP-Bang questionnaire and NoSAS score) were found to be adequate instruments for OSA screening at any severity level. The use of these instruments can allow improved allocation of patients into corresponding priorities, thus enabling better prioritization of financial resources. In both cohorts, there was no superiority of one given tool over the other, which shows a possible great practical applicability of the GOAL questionnaire, as it contains only four clinical parameters easily obtained during any evaluation of a patient with suspected OSA. As with any population study, future exploration for other world regions and different clinical settings will be critical for widespread implementation of such simple and concise screening tool.</citation_analysis></p>
    </sec>
  </body>
  <back>
    <sec id="S0006" sec-type="COI-statement">
      <title>Disclosure</title>
      <p><citation_analysis attribute="neither">The authors declare no conflicts of interest.</citation_analysis></p>
    </sec>
    <ref-list>
      <title>References</title>
      <ref id="CIT0001">
        <label>1.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Kapur</surname>
<given-names>VK</given-names></string-name>, <string-name><surname>Auckley</surname>
<given-names>DH</given-names></string-name>, <string-name><surname>Chowdhuri</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine clinical practice guideline</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2017</year>;<volume>13</volume>(<issue>3</issue>):<fpage>479</fpage>–<lpage>504</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.6506</pub-id><pub-id pub-id-type="pmid">28162150</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0002">
        <label>2.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Marshall</surname>
<given-names>NS</given-names></string-name>, <string-name><surname>Delling</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Grunstein</surname>
<given-names>RR</given-names></string-name>, et al. <article-title>Self-reported sleep-apnoea and mortality from the Swedish obese subjects study</article-title>. <source><italic toggle="yes">Eur Respir J</italic></source>. <year>2011</year>;<volume>38</volume>(<issue>6</issue>):<fpage>1349</fpage>–<lpage>1354</lpage>. doi:<pub-id pub-id-type="doi">10.1183/09031936.00022111</pub-id><pub-id pub-id-type="pmid">21622591</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0003">
        <label>3.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Pelletier-Fleury</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Meslier</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Gagnadoux</surname>
<given-names>F</given-names></string-name>, et al. <article-title>Economic arguments for the immediate management of moderate-to-severe obstructive sleep apnoea syndrome</article-title>. <source><italic toggle="yes">Eur Respir J</italic></source>. <year>2004</year>;<volume>23</volume>(<issue>1</issue>):<fpage>53</fpage>–<lpage>60</lpage>. doi:<pub-id pub-id-type="doi">10.1183/09031936.03.00066903</pub-id><pub-id pub-id-type="pmid">14738231</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0004">
        <label>4.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Peppard</surname>
<given-names>PE</given-names></string-name>, <string-name><surname>Young</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Barnet</surname>
<given-names>JH</given-names></string-name>, et al. <article-title>Increased prevalence of sleep-disordered breathing in adults</article-title>. <source><italic toggle="yes">Am J Epidemiol</italic></source>. <year>2013</year>;<volume>177</volume>(<issue>9</issue>):<fpage>1006</fpage>–<lpage>1014</lpage>. doi:<pub-id pub-id-type="doi">10.1093/aje/kws342</pub-id><pub-id pub-id-type="pmid">23589584</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0005">
        <label>5.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Heinzer</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Vat</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Marques-Vidal</surname>
<given-names>P</given-names></string-name>, et al. <article-title>Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study</article-title>. <source><italic toggle="yes">Lancet Respir Med</italic></source>. <year>2015</year>;<volume>3</volume>(<issue>4</issue>):<fpage>310</fpage>–<lpage>318</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2213-2600(15)00043-0</pub-id><pub-id pub-id-type="pmid">25682233</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0006">
        <label>6.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Tufik</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Santos-Silva</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Taddei</surname>
<given-names>JA</given-names></string-name>, et al. <article-title>Obstructive sleep apnea syndrome in the Sao Paulo epidemiologic sleep study</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2010</year>;<volume>11</volume>(<issue>5</issue>):<fpage>441</fpage>–<lpage>446</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2009.10.005</pub-id><pub-id pub-id-type="pmid">20362502</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0007">
        <label>7.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Benjafield</surname>
<given-names>AV</given-names></string-name>, <string-name><surname>Ayas</surname>
<given-names>NT</given-names></string-name>, <string-name><surname>Eastwood</surname>
<given-names>PR</given-names></string-name>, et al. <article-title>Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis</article-title>. <source><italic toggle="yes">Lancet Respir Med</italic></source>. <year>2019</year>;<volume>7</volume>(<issue>8</issue>):<fpage>687</fpage>–<lpage>698</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2213-2600(19)30198-5</pub-id><pub-id pub-id-type="pmid">31300334</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0008">
        <label>8.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Abrishami</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Khajehdehi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Chung</surname>
<given-names>F</given-names></string-name>. <article-title>A systematic review of screening questionnaires for obstructive sleep apnea</article-title>. <source><italic toggle="yes">Can J Anesth</italic></source>. <year>2010</year>;<volume>57</volume>(<issue>5</issue>):<fpage>423</fpage>–<lpage>438</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12630-010-9280-x</pub-id><pub-id pub-id-type="pmid">20143278</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0009">
        <label>9.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Rotenberg</surname>
<given-names>B</given-names></string-name>, <string-name><surname>George</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Sullivan</surname>
<given-names>K</given-names></string-name>, et al. <article-title>Wait times for sleep apnea care in Ontario: a multidisciplinary assessment</article-title>. <source><italic toggle="yes">Can Resp J</italic></source>. <year>2010</year>;<volume>17</volume>(<issue>4</issue>):<fpage>170</fpage>–<lpage>174</lpage>.</mixed-citation>
      </ref>
      <ref id="CIT0010">
        <label>10.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Chung</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Yegneswaran</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Liao</surname>
<given-names>P</given-names></string-name>, et al. <article-title>STOP questionnaire: a tool to screen patients for obstructive sleep apnea</article-title>. <source><italic toggle="yes">Anesthesiology</italic></source>. <year>2008</year>;<volume>108</volume>(<issue>5</issue>):<fpage>812</fpage>–<lpage>821</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ALN.0b013e31816d83e4</pub-id><pub-id pub-id-type="pmid">18431116</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0011">
        <label>11.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Duarte</surname>
<given-names>RLM</given-names></string-name>, <string-name><surname>Fonseca</surname>
<given-names>LBM</given-names></string-name>, <string-name><surname>Magalhães-da-Silveira</surname>
<given-names>FJ</given-names></string-name>, et al. <article-title>Validation of the STOP-Bang questionnaire as a means of screening for obstructive sleep apnea in adults in Brazil</article-title>. <source><italic toggle="yes">J Bras Pneumol</italic></source>. <year>2017</year>;<volume>43</volume>(<issue>6</issue>):<fpage>456</fpage>–<lpage>463</lpage>. doi:<pub-id pub-id-type="doi">10.1590/S1806-37562017000000139</pub-id><pub-id pub-id-type="pmid">29340495</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0012">
        <label>12.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Miller</surname>
<given-names>JN</given-names></string-name>, <string-name><surname>Kupzyk</surname>
<given-names>KA</given-names></string-name>, <string-name><surname>Zimmerman</surname>
<given-names>L</given-names></string-name>, et al. <article-title>Comparisons of measures used to screen for obstructive sleep apnea in patients referred to a sleep clinic</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2018</year>;<volume>51</volume>:<fpage>15</fpage>–<lpage>21</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2018.06.007</pub-id><pub-id pub-id-type="pmid">30077956</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0013">
        <label>13.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Chia</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Seet</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Macachor</surname>
<given-names>JD</given-names></string-name>, et al. <article-title>The association of preoperative STOP-Bang scores with postoperative critical care admission</article-title>. <source><italic toggle="yes">Anaesthesia</italic></source>. <year>2013</year>;<volume>68</volume>(<issue>9</issue>):<fpage>950</fpage>–<lpage>952</lpage>. doi:<pub-id pub-id-type="doi">10.1111/anae.12369</pub-id><pub-id pub-id-type="pmid">23848465</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0014">
        <label>14.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Nagappa</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Patra</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Wong</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Association of STOP-Bang questionnaire as a screening tool for sleep apnea and postoperative complications: a systematic review and Bayesian meta-analysis of prospective and retrospective cohort studies</article-title>. <source><italic toggle="yes">Anesth Analg</italic></source>. <year>2017</year>;<volume>125</volume>(<issue>4</issue>):<fpage>1301</fpage>–<lpage>1308</lpage>. doi:<pub-id pub-id-type="doi">10.1213/ANE.0000000000002344</pub-id><pub-id pub-id-type="pmid">28817421</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0015">
        <label>15.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Silva</surname>
<given-names>GE</given-names></string-name>, <string-name><surname>Vana</surname>
<given-names>KD</given-names></string-name>, <string-name><surname>Goodwin</surname>
<given-names>JL</given-names></string-name>, et al. <article-title>Identification of patients with sleep disordered breathing: comparing the four-variable screening tool, STOP, STOP-Bang, and Epworth sleepiness scales</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2011</year>;<volume>7</volume>(<issue>5</issue>):<fpage>467</fpage>–<lpage>472</lpage>. doi:<pub-id pub-id-type="doi">10.5664/JCSM.1308</pub-id><pub-id pub-id-type="pmid">22003341</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0016">
        <label>16.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Tan</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Yin</surname>
<given-names>JD</given-names></string-name>, <string-name><surname>Tan</surname>
<given-names>LW</given-names></string-name>, et al. <article-title>Predicting obstructive sleep apnea using the STOP-Bang questionnaire in the general population</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2016</year>;<volume>27–28</volume>:<fpage>66</fpage>–<lpage>71</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2016.06.034</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0017">
        <label>17.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Marti-Soler</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Hirotsu</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Marques-Vidal</surname>
<given-names>P</given-names></string-name>, et al. <article-title>The NoSAS score for screening of sleep-disordered breathing: a derivation and validation study</article-title>. <source><italic toggle="yes">Lancet Respir Med</italic></source>. <year>2016</year>;<volume>4</volume>(<issue>9</issue>):<fpage>742</fpage>–<lpage>748</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2213-2600(16)30075-3</pub-id><pub-id pub-id-type="pmid">27321086</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0018">
        <label>18.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Tan</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hong</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Tan</surname>
<given-names>LWL</given-names></string-name>, et al. <article-title>Validation of NoSAS score for screening of sleep-disordered breathing in a multiethnic Asian population</article-title>. <source><italic toggle="yes">Sleep Breath</italic></source>. <year>2017</year>;<volume>21</volume>(<issue>4</issue>):<fpage>1033</fpage>–<lpage>1038</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11325-016-1455-4</pub-id><pub-id pub-id-type="pmid">28064432</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0019">
        <label>19.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Hong</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Qing</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Validation of the NoSAS score for the screening of sleep-disordered breathing: a hospital-based retrospective study in China</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2018</year>;<volume>14</volume>(<issue>2</issue>):<fpage>191</fpage>–<lpage>197</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.6930</pub-id><pub-id pub-id-type="pmid">29394959</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0020">
        <label>20.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Peng</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Cheng</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Application value of the NoSAS score for screening sleep-disordered breathing</article-title>. <source><italic toggle="yes">J Thorac Dis</italic></source>. <year>2018</year>;<volume>10</volume>(<issue>8</issue>):<fpage>4774</fpage>–<lpage>4781</lpage>. doi:<pub-id pub-id-type="doi">10.21037/jtd.2018.07.46</pub-id><pub-id pub-id-type="pmid">30233849</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0021">
        <label>21.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Guichard</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Marti-Soler</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Micoulaud-Franchi</surname>
<given-names>JA</given-names></string-name>, et al. <article-title>The NoSAS score: a new and simple screening tool for obstructive sleep apnea syndrome in depressive disorder</article-title>. <source><italic toggle="yes">J Affect Disord</italic></source>. <year>2018</year>;<volume>227</volume>:<fpage>136</fpage>–<lpage>140</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jad.2017.10.015</pub-id><pub-id pub-id-type="pmid">29055261</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0022">
        <label>22.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Coutinho Costa</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Rebelo-Marques</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Machado</surname>
<given-names>JN</given-names></string-name>, et al. <article-title>Validation of NoSAS (neck, obesity, snoring, age, sex) score as a screening tool for obstructive sleep apnea: analysis in a sleep clinic</article-title>. <source><italic toggle="yes">Pulmonology</italic></source>. <year>2019</year>;<volume>25</volume>(<issue>5</issue>):<fpage>263</fpage>–<lpage>270</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pulmoe.2019.04.004</pub-id><pub-id pub-id-type="pmid">31196834</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0023">
        <label>23.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Duarte</surname>
<given-names>RL</given-names></string-name>, <string-name><surname>Rabahi</surname>
<given-names>MF</given-names></string-name>, <string-name><surname>Magalhães-da-Silveira</surname>
<given-names>FJ</given-names></string-name>, et al. <article-title>Simplifying the screening of obstructive sleep apnea with a 2-item model, No-Apnea: a cross-sectional study</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2018</year>;<volume>14</volume>(<issue>7</issue>):<fpage>1097</fpage>–<lpage>1107</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.7202</pub-id><pub-id pub-id-type="pmid">29991419</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0024">
        <label>24.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Duarte</surname>
<given-names>RLM</given-names></string-name>, <string-name><surname>Rabahi</surname>
<given-names>MF</given-names></string-name>, <string-name><surname>Oliveira-e-Sá</surname>
<given-names>TS</given-names></string-name>, et al. <article-title>Fractional exhaled nitric oxide measurements and screening of obstructive sleep apnea in a sleep-laboratory setting: a cross-sectional study</article-title>. <source><italic toggle="yes">Lung</italic></source>. <year>2019</year>;<volume>197</volume>(<issue>2</issue>):<fpage>131</fpage>–<lpage>137</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00408-018-0190-y</pub-id><pub-id pub-id-type="pmid">30600394</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0025">
        <label>25.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Duarte</surname>
<given-names>RLM</given-names></string-name>, <string-name><surname>Mello</surname>
<given-names>FCQ</given-names></string-name>, <string-name><surname>Magalhães-da-Silveira</surname>
<given-names>FJ</given-names></string-name>, et al. <article-title>Comparative performance of screening instruments for obstructive sleep apnea in morbidly obese patients referred to a sleep laboratory: a prospective cross-sectional study</article-title>. <source><italic toggle="yes">Sleep Breath</italic></source>. <year>2019</year>;<volume>23</volume>(<issue>4</issue>):<fpage>1123</fpage>–<lpage>1132</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11325-019-01791-w</pub-id><pub-id pub-id-type="pmid">30734890</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0026">
        <label>26.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Duarte</surname>
<given-names>RLM</given-names></string-name>, <string-name><surname>Magalhães-da-Silveira</surname>
<given-names>FJ</given-names></string-name>, <string-name><surname>Oliveira-e-Sá</surname>
<given-names>TS</given-names></string-name>, et al. <article-title>Predicting obstructive sleep apnea in patients with insomnia: a comparative study with four screening instruments</article-title>. <source><italic toggle="yes">Lung</italic></source>. <year>2019</year>;<volume>197</volume>(<issue>4</issue>):<fpage>451</fpage>–<lpage>458</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00408-019-00232-5</pub-id><pub-id pub-id-type="pmid">31076859</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0027">
        <label>27.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Johns</surname>
<given-names>MW</given-names></string-name>. <article-title>A new method for measuring daytime sleepiness: the Epworth sleepiness scale</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>1991</year>;<volume>14</volume>(<issue>6</issue>):<fpage>540</fpage>–<lpage>545</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/14.6.540</pub-id><pub-id pub-id-type="pmid">1798888</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0028">
        <label>28.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Berry</surname>
<given-names>RB</given-names></string-name>, <string-name><surname>Budhiraja</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Gottlieb</surname>
<given-names>DJ</given-names></string-name>, et al. <article-title>Rules for scoring respiratory events in sleep: update of the 2007 AASM manual for the scoring of sleep and associated events</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2012</year>;<volume>8</volume>(<issue>5</issue>):<fpage>597</fpage>–<lpage>619</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.2172</pub-id><pub-id pub-id-type="pmid">23066376</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0029">
        <label>29.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Hanley</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>McNeil</surname>
<given-names>BJ</given-names></string-name>. <article-title>A method of comparing the areas under receiver operating characteristic curves derived from the same cases</article-title>. <source><italic toggle="yes">Radiology</italic></source>. <year>1983</year>;<volume>148</volume>(<issue>3</issue>):<fpage>839</fpage>–<lpage>843</lpage>. doi:<pub-id pub-id-type="doi">10.1148/radiology.148.3.6878708</pub-id><pub-id pub-id-type="pmid">6878708</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0030">
        <label>30.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Senaratna</surname>
<given-names>CV</given-names></string-name>, <string-name><surname>Perret</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Matheson</surname>
<given-names>MC</given-names></string-name>, et al. <article-title>Validity of the Berlin questionnaire in detecting obstructive sleep apnea: a systematic review and meta-analysis</article-title>. <source><italic toggle="yes">Sleep Med Rev</italic></source>. <year>2007</year>;<volume>36</volume>:<fpage>116</fpage>–<lpage>124</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.smrv.2017.04.001</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0031">
        <label>31.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Chung</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Subramanyam</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Liao</surname>
<given-names>P</given-names></string-name>, et al. <article-title>High STOP-Bang score indicates a high probability of obstructive sleep apnoea</article-title>. <source><italic toggle="yes">Br J Anaesth</italic></source>. <year>2012</year>;<volume>108</volume>(<issue>5</issue>):<fpage>768</fpage>–<lpage>775</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bja/aes022</pub-id><pub-id pub-id-type="pmid">22401881</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0032">
        <label>32.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Basoglu</surname>
<given-names>OK</given-names></string-name>, <string-name><surname>Tasbakan</surname>
<given-names>MS</given-names></string-name>. <article-title>Gender differences in clinical and polysomnographic features of obstructive sleep apnea: a clinical study of 2827 patients</article-title>. <source><italic toggle="yes">Sleep Breath</italic></source>. <year>2018</year>;<volume>22</volume>(<issue>1</issue>):<fpage>241</fpage>–<lpage>249</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11325-017-1482-9</pub-id><pub-id pub-id-type="pmid">28197893</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0033">
        <label>33.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Nigro</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Dibur</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Borsini</surname>
<given-names>E</given-names></string-name>, et al. <article-title>The influence of gender on symptoms associated with obstructive sleep apnea</article-title>. <source><italic toggle="yes">Sleep Breath</italic></source>. <year>2018</year>;<volume>22</volume>(<issue>3</issue>):<fpage>683</fpage>–<lpage>693</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11325-017-1612-4</pub-id><pub-id pub-id-type="pmid">29392572</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0034">
        <label>34.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Dancey</surname>
<given-names>DR</given-names></string-name>, <string-name><surname>Hanly</surname>
<given-names>PJ</given-names></string-name>, <string-name><surname>Soong</surname>
<given-names>C</given-names></string-name>, et al. <article-title>Gender differences in sleep apnea: the role of neck circumference</article-title>. <source><italic toggle="yes">Chest</italic></source>. <year>2003</year>;<volume>123</volume>(<issue>5</issue>):<fpage>1544</fpage>–<lpage>1550</lpage>. doi:<pub-id pub-id-type="doi">10.1378/chest.123.5.1544</pub-id><pub-id pub-id-type="pmid">12740272</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0035">
        <label>35.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Fietze</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Laharnar</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Obst</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Prevalence and association analysis of obstructive sleep apnea with gender and age differences - Results of SHIP-Trend</article-title>. <source><italic toggle="yes">J Sleep Res</italic></source>. <year>2019</year>;<volume>28</volume>(<issue>5</issue>):<fpage>e12770</fpage>. doi:<pub-id pub-id-type="doi">10.1111/jsr.12770</pub-id><pub-id pub-id-type="pmid">30272383</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0036">
        <label>36.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Maimon</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Hanly</surname>
<given-names>PJ</given-names></string-name>. <article-title>Does snoring intensity correlate with the severity of obstructive sleep apnea?</article-title>
<source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2010</year>;<volume>6</volume>(<issue>5</issue>):<fpage>475</fpage>–<lpage>478</lpage>.<pub-id pub-id-type="pmid">20957849</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0037">
        <label>37.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Fonseca</surname>
<given-names>LB</given-names></string-name>, <string-name><surname>Silveira</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Lima</surname>
<given-names>NM</given-names></string-name>, et al. <article-title>STOP-Bang questionnaire: translation to Portuguese and cross-cultural adaptation for use in Brazil</article-title>. <source><italic toggle="yes">J Bras Pneumol</italic></source>. <year>2016</year>;<volume>42</volume>(<issue>4</issue>):<fpage>266</fpage>–<lpage>272</lpage>. doi:<pub-id pub-id-type="doi">10.1590/S1806-37562015000000243</pub-id><pub-id pub-id-type="pmid">27832234</pub-id></mixed-citation>
      </ref>
      <ref id="CIT0038">
        <label>38.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ramachandran</surname>
<given-names>SK</given-names></string-name>, <string-name><surname>Josephs</surname>
<given-names>LA</given-names></string-name>. <article-title>A meta-analysis of clinical screening tests for obstructive sleep apnea</article-title>. <source><italic toggle="yes">Anesthesiology</italic></source>. <year>2009</year>;<volume>110</volume>(<issue>4</issue>):<fpage>928</fpage>–<lpage>939</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ALN.0b013e31819c47b6</pub-id><pub-id pub-id-type="pmid">19293704</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
